Sensitive HIV-1 DNA Pol Next-Generation Sequencing for the Characterisation of Archived Antiretroviral Drug Resistance-Reference-Cited by-同舟云学术

Sensitive HIV-1 DNA Pol Next-Generation Sequencing for the Characterisation of Archived Antiretroviral Drug Resistance

Published:2023-08-25 Issue:9 Volume:15 Page:1811
ISSN:1999-4915
Container-title:Viruses
language:en
Short-container-title:Viruses

Author:

Botha Johannes C.¹²^ORCID,Byott Matthew¹²,Spyer Moira J.¹²,Grant Paul R.³,Gärtner Kathleen¹,Chen Wilson X.⁴,Burton James⁵,Bamford Alasdair¹⁵⁶,Waters Laura J.⁷,Giaquinto Carlo⁸⁹,Turkova Anna⁵⁶^ORCID,Vavro Cindy L.⁴,Nastouli Eleni¹²

Affiliation:

1. Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK

2. Advanced Pathogen Diagnostics Unit, University College London Hospitals NHS Trust, London NW1 2PG, UK

3. Health Services Laboratories, London WC1H 9AX, UK

4. ViiV Healthcare, Durham, NC 27709, USA

5. Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK

6. Medical Research Council Clinical Trials Unit, University College London, London WC1E 6BT, UK

7. Central and North West London NHS Foundation Trust, Mortimer Market, London WC1E 6JB, UK

8. Department of Women and Child Health, University of Padova, 35122 Padova, Italy

9. Fondazione Penta ETS, 35127 Padova, Italy

Abstract

Modern HIV-1 treatment effectively suppresses viral amplification in people living with HIV. However, the persistence of HIV-1 DNA as proviruses integrated into the human genome remains the main barrier to achieving a cure. Next-generation sequencing (NGS) offers increased sensitivity for characterising archived drug resistance mutations (DRMs) in HIV-1 DNA for improved treatment options. In this study, we present an ultra-sensitive targeted PCR assay coupled with NGS and a robust pipeline to characterise HIV-1 DNA DRMs from buffy coat samples. Our evaluation supports the use of this assay for Pan-HIV-1 analyses with reliable detection of DRMs across the HIV-1 Pol region. We propose this assay as a new valuable tool for monitoring archived HIV-1 drug resistance in virologically suppressed individuals, especially in clinical trials investigating novel therapeutic approaches.

Funder

D3/Penta 21 trial

ViiV Healthcare

UCLH APDU

UK Medical Research Council core funding

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

Link

https://www.mdpi.com/1999-4915/15/9/1811/pdf

Reference32 articles.

1. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents (2023, May 19). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, Available online: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf.

2. European AIDS Clinical Society (2023, May 19). Guidelines Version 11.0 October 2021. Available online: https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf.

3. Presence of an Inducible HIV-1 Latent Reservoir during Highly Active Antiretroviral Therapy;Chun;Proc. Natl. Acad. Sci. USA,1997

4. Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy;Finzi;Science,1997

5. Genetic Characterization of HIV-1 from Semen and Blood from Clade C-Infected Subjects from India and Effect of Therapy in These Body Compartments;Shen;Virology,2010

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years;Contemporary Clinical Trials;2024-07